South Denver Cardiology Associates
South Denver Cardiology Associates
Littleton, Colorado, United States6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06531824 | |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | Angina Pectoris, Chest Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-09-30 | NCT05102019 | |
| A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Enrolling by invitation | Not stated | 2026-08-27 | NCT06335082 | |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-08-21 | NCT07136012 | |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, atrial septal defect, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, congenital heart disease, heart disorder, heart septal defect, nervous system disorder, patent foramen ovale, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-07-30 | NCT03821129 | |
| Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, atrial septal defect, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, congenital heart disease, heart disorder, heart septal defect, nervous system disorder, patent foramen ovale, stroke disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-05-22 | NCT05069558 |